Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-08

AUTHORS

Anna Maria Di Giacomo, Riccardo Danielli, Massimo Guidoboni, Luana Calabrò, Dora Carlucci, Clelia Miracco, Luca Volterrani, Maria Antonietta Mazzei, Maurizio Biagioli, Maresa Altomonte, Michele Maio

ABSTRACT

The management of unresectable metastatic melanoma is a major clinical challenge because of the lack of reliably effective systemic therapies. Blocking cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) has recently been proposed as a strategy to enhance cell-mediated immune responses to cancer, and clinical trials have demonstrated that anti-CTLA-4 therapy can produce durable outcomes with different response patterns than cytotoxic chemotherapy. We enrolled eight out of 155 patients with advanced melanoma in a multicentre phase II trial that evaluated the activity and tolerability of ipilimumab, a fully human, anti-CTLA-4 monoclonal antibody ( www.clinicaltrials.gov ; NCT00289627; CA184-008). Here we report our experience with three of these patients, who experienced progressive disease after a variety of previous therapies, including prior immunotherapies, and who achieved good outcomes with ipilimumab. One patient had a partial response ongoing at 17+ months on ipilimumab despite failure with four prior therapies, and the other two patients showed durable stable disease, both still ongoing at 17+ and 20+ months, respectively. The patient achieving a partial response experienced no side effects while receiving ipilimumab. The other two patients developed immune-related adverse events (irAEs) including rash (one case; grade 2) and diarrhoea (both cases; grades 1 and 2, respectively); the histopathology of colon biopsy samples from both was suggestive of colitis, with an abundant CD8+ T-cell infiltrate. Nausea, vomiting and acute pancreatitis were also observed in one patient. In addition, immunohistochemical findings of a dense CD8+, TIA1+ and granzyme B+ lymphoid infiltrate within a biopsied lesion provide indirect evidence of functional T-cell activation induced by treatment. These case reports highlight the potential for anti-CTLA-4-based therapy in previously treated patients with advanced melanoma. Moreover, because the patterns of response to ipilimumab differ from chemotherapy, we need to understand how and when patients may respond to treatment so that appropriate clinical decisions can be made. More... »

PAGES

1297-1306

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00262-008-0642-y

DOI

http://dx.doi.org/10.1007/s00262-008-0642-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1015704592

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19139884


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, CD", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CD8 Antigens", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CD8-Positive T-Lymphocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CTLA-4 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Granzymes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ipilimumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Poly(A)-Binding Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Skin Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "T-Cell Intracellular Antigen-1", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Universitaria Senese", 
          "id": "https://www.grid.ac/institutes/grid.411477.0", 
          "name": [
            "Division of Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di Giacomo", 
        "givenName": "Anna Maria", 
        "id": "sg:person.01116772254.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116772254.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Universitaria Senese", 
          "id": "https://www.grid.ac/institutes/grid.411477.0", 
          "name": [
            "Division of Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Danielli", 
        "givenName": "Riccardo", 
        "id": "sg:person.01070050076.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070050076.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Universitaria Senese", 
          "id": "https://www.grid.ac/institutes/grid.411477.0", 
          "name": [
            "Division of Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guidoboni", 
        "givenName": "Massimo", 
        "id": "sg:person.0603211266.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603211266.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Universitaria Senese", 
          "id": "https://www.grid.ac/institutes/grid.411477.0", 
          "name": [
            "Division of Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Calabr\u00f2", 
        "givenName": "Luana", 
        "id": "sg:person.01050657054.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050657054.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Universitaria Senese", 
          "id": "https://www.grid.ac/institutes/grid.411477.0", 
          "name": [
            "Division of Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carlucci", 
        "givenName": "Dora", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Universitaria Senese", 
          "id": "https://www.grid.ac/institutes/grid.411477.0", 
          "name": [
            "Department of Pathology, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miracco", 
        "givenName": "Clelia", 
        "id": "sg:person.0740661020.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740661020.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Universitaria Senese", 
          "id": "https://www.grid.ac/institutes/grid.411477.0", 
          "name": [
            "Department of Radiology, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Volterrani", 
        "givenName": "Luca", 
        "id": "sg:person.01360274573.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360274573.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Universitaria Senese", 
          "id": "https://www.grid.ac/institutes/grid.411477.0", 
          "name": [
            "Department of Radiology, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mazzei", 
        "givenName": "Maria Antonietta", 
        "id": "sg:person.01352632550.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352632550.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Universitaria Senese", 
          "id": "https://www.grid.ac/institutes/grid.411477.0", 
          "name": [
            "Division of Dermatology, Istitutto Toscano Tumori, University Hospital of Siena, Siena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Biagioli", 
        "givenName": "Maurizio", 
        "id": "sg:person.01063522603.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063522603.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Universitaria Senese", 
          "id": "https://www.grid.ac/institutes/grid.411477.0", 
          "name": [
            "Division of Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Altomonte", 
        "givenName": "Maresa", 
        "id": "sg:person.01123052323.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123052323.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centro di Riferimento Oncologico", 
          "id": "https://www.grid.ac/institutes/grid.418321.d", 
          "name": [
            "Division of Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy", 
            "Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maio", 
        "givenName": "Michele", 
        "id": "sg:person.01061427172.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061427172.10"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2006.10.2822", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001819704"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.cji.0000208259.73167.58", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003604986"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.cji.0000208259.73167.58", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003604986"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.cji.0000208259.73167.58", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003604986"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.04.5716", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003868054"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.23086", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010896709"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000082121", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011274228"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.12-7-864", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016305749"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.06.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021025524"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.06.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021025524"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.soc.2005.12.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023784292"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1359-6349(07)71459-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029251445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd005413.pub2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037337648"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.7.2105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549817"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077591019", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.23.16_suppl.7525", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079369791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.26.15_suppl.3008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079371247"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.26.15_suppl.3020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079371250"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.26.15_suppl.9063", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079374683"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-08", 
    "datePublishedReg": "2009-08-01", 
    "description": "The management of unresectable metastatic melanoma is a major clinical challenge because of the lack of reliably effective systemic therapies. Blocking cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) has recently been proposed as a strategy to enhance cell-mediated immune responses to cancer, and clinical trials have demonstrated that anti-CTLA-4 therapy can produce durable outcomes with different response patterns than cytotoxic chemotherapy. We enrolled eight out of 155 patients with advanced melanoma in a multicentre phase II trial that evaluated the activity and tolerability of ipilimumab, a fully human, anti-CTLA-4 monoclonal antibody ( www.clinicaltrials.gov ; NCT00289627; CA184-008). Here we report our experience with three of these patients, who experienced progressive disease after a variety of previous therapies, including prior immunotherapies, and who achieved good outcomes with ipilimumab. One patient had a partial response ongoing at 17+ months on ipilimumab despite failure with four prior therapies, and the other two patients showed durable stable disease, both still ongoing at 17+ and 20+ months, respectively. The patient achieving a partial response experienced no side effects while receiving ipilimumab. The other two patients developed immune-related adverse events (irAEs) including rash (one case; grade 2) and diarrhoea (both cases; grades 1 and 2, respectively); the histopathology of colon biopsy samples from both was suggestive of colitis, with an abundant CD8+ T-cell infiltrate. Nausea, vomiting and acute pancreatitis were also observed in one patient. In addition, immunohistochemical findings of a dense CD8+, TIA1+ and granzyme B+ lymphoid infiltrate within a biopsied lesion provide indirect evidence of functional T-cell activation induced by treatment. These case reports highlight the potential for anti-CTLA-4-based therapy in previously treated patients with advanced melanoma. Moreover, because the patterns of response to ipilimumab differ from chemotherapy, we need to understand how and when patients may respond to treatment so that appropriate clinical decisions can be made.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00262-008-0642-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096240", 
        "issn": [
          "0340-7004", 
          "1432-0851"
        ], 
        "name": "Cancer Immunology, Immunotherapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "58"
      }
    ], 
    "name": "Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases", 
    "pagination": "1297-1306", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "4ad3643b910511b73e6ea79ffec86cb6693f0483d8ac9086bd5b2c920bb7edbc"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19139884"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8605732"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00262-008-0642-y"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1015704592"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00262-008-0642-y", 
      "https://app.dimensions.ai/details/publication/pub.1015704592"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T15:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8664_00000531.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00262-008-0642-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00262-008-0642-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00262-008-0642-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00262-008-0642-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00262-008-0642-y'


 

This table displays all metadata directly associated to this object as RDF triples.

260 TRIPLES      21 PREDICATES      62 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00262-008-0642-y schema:about N24b14f55008d4439995cff81944d4b3d
2 N32923e6bbc5744758424fe2253d81d24
3 N359ee2e1936444ad84817b063512e1e2
4 N422e46941b2f400d85451e322a8a80ba
5 N5354a8b0a6d34969ad0b1e8c87c99696
6 N5d68c2b06c41491f8aaf4f03e404024f
7 N7e4eefb06c7348959a447392f07e48af
8 N882f66cdcf1a4cfa8e40c4e94f6770c9
9 N8b307d9293054838aeecda606d5d61ad
10 N9120216f653548218edf9b778271636a
11 Naf233fe2c8454130bdf5eb9d4514695c
12 Nda9e33c64e0e4c47ac5d1331141ae371
13 Ne2f5f71e74cb413b8cd66bc49f4b247a
14 Neadbb01d137d46778b08be43ea0624e7
15 Nedf1b74a07f84b5796589aa8db043812
16 Nf4ead7b65e864f3ead01b56771997611
17 Nf53262e478664c1fb5d3c749972f010a
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author Na629c83e42e94428b0a698a5e50cd176
21 schema:citation https://app.dimensions.ai/details/publication/pub.1077591019
22 https://doi.org/10.1002/14651858.cd005413.pub2
23 https://doi.org/10.1002/cncr.23086
24 https://doi.org/10.1016/j.soc.2005.12.002
25 https://doi.org/10.1016/s1359-6349(07)71459-3
26 https://doi.org/10.1097/01.cji.0000208259.73167.58
27 https://doi.org/10.1159/000082121
28 https://doi.org/10.1200/jco.1999.17.7.2105
29 https://doi.org/10.1200/jco.2005.04.5716
30 https://doi.org/10.1200/jco.2005.06.205
31 https://doi.org/10.1200/jco.2005.23.16_suppl.7525
32 https://doi.org/10.1200/jco.2006.10.2822
33 https://doi.org/10.1200/jco.2008.26.15_suppl.3008
34 https://doi.org/10.1200/jco.2008.26.15_suppl.3020
35 https://doi.org/10.1200/jco.2008.26.15_suppl.9063
36 https://doi.org/10.1634/theoncologist.12-7-864
37 schema:datePublished 2009-08
38 schema:datePublishedReg 2009-08-01
39 schema:description The management of unresectable metastatic melanoma is a major clinical challenge because of the lack of reliably effective systemic therapies. Blocking cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) has recently been proposed as a strategy to enhance cell-mediated immune responses to cancer, and clinical trials have demonstrated that anti-CTLA-4 therapy can produce durable outcomes with different response patterns than cytotoxic chemotherapy. We enrolled eight out of 155 patients with advanced melanoma in a multicentre phase II trial that evaluated the activity and tolerability of ipilimumab, a fully human, anti-CTLA-4 monoclonal antibody ( www.clinicaltrials.gov ; NCT00289627; CA184-008). Here we report our experience with three of these patients, who experienced progressive disease after a variety of previous therapies, including prior immunotherapies, and who achieved good outcomes with ipilimumab. One patient had a partial response ongoing at 17+ months on ipilimumab despite failure with four prior therapies, and the other two patients showed durable stable disease, both still ongoing at 17+ and 20+ months, respectively. The patient achieving a partial response experienced no side effects while receiving ipilimumab. The other two patients developed immune-related adverse events (irAEs) including rash (one case; grade 2) and diarrhoea (both cases; grades 1 and 2, respectively); the histopathology of colon biopsy samples from both was suggestive of colitis, with an abundant CD8+ T-cell infiltrate. Nausea, vomiting and acute pancreatitis were also observed in one patient. In addition, immunohistochemical findings of a dense CD8+, TIA1+ and granzyme B+ lymphoid infiltrate within a biopsied lesion provide indirect evidence of functional T-cell activation induced by treatment. These case reports highlight the potential for anti-CTLA-4-based therapy in previously treated patients with advanced melanoma. Moreover, because the patterns of response to ipilimumab differ from chemotherapy, we need to understand how and when patients may respond to treatment so that appropriate clinical decisions can be made.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree false
43 schema:isPartOf Na76ce23143bd4623bc4443495b322965
44 Nb1e18d44975b42c2aba2af424bbce1f7
45 sg:journal.1096240
46 schema:name Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
47 schema:pagination 1297-1306
48 schema:productId N0a24bdc630aa47bba5bb3f2639abc7f8
49 N52032bb303e14b53ad267d1d12f29c42
50 N707d4805e5874f63a7263e3bc86a9da2
51 Nb83199ab97ce4a35895c0c8bdc57b409
52 Ne1b08611521842ff9b4f0a5760a980b1
53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015704592
54 https://doi.org/10.1007/s00262-008-0642-y
55 schema:sdDatePublished 2019-04-10T15:55
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher N5a723daa39cd4a458c830e2ef4233463
58 schema:url http://link.springer.com/10.1007%2Fs00262-008-0642-y
59 sgo:license sg:explorer/license/
60 sgo:sdDataset articles
61 rdf:type schema:ScholarlyArticle
62 N0a24bdc630aa47bba5bb3f2639abc7f8 schema:name dimensions_id
63 schema:value pub.1015704592
64 rdf:type schema:PropertyValue
65 N24b14f55008d4439995cff81944d4b3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name CD8-Positive T-Lymphocytes
67 rdf:type schema:DefinedTerm
68 N283d770b15e5497bad0d4ff6d4d09abf rdf:first sg:person.01063522603.80
69 rdf:rest Na939490b34d342d596a21c02fdfc05e6
70 N32923e6bbc5744758424fe2253d81d24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name T-Cell Intracellular Antigen-1
72 rdf:type schema:DefinedTerm
73 N359ee2e1936444ad84817b063512e1e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name CD8 Antigens
75 rdf:type schema:DefinedTerm
76 N38b53e9cec304407a14645323f03e74d rdf:first sg:person.01061427172.10
77 rdf:rest rdf:nil
78 N3be1faa63fe545f3bdf19c762b4fb954 rdf:first sg:person.01050657054.88
79 rdf:rest Nfa23e3b31cc445d1840e93161c17e271
80 N422e46941b2f400d85451e322a8a80ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Poly(A)-Binding Proteins
82 rdf:type schema:DefinedTerm
83 N52032bb303e14b53ad267d1d12f29c42 schema:name pubmed_id
84 schema:value 19139884
85 rdf:type schema:PropertyValue
86 N5354a8b0a6d34969ad0b1e8c87c99696 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Melanoma
88 rdf:type schema:DefinedTerm
89 N563e5890cefd4b81b42dbf1bc2cb2bf0 rdf:first sg:person.01360274573.21
90 rdf:rest N640289673c4f4ee99871349c7a270e2f
91 N5a723daa39cd4a458c830e2ef4233463 schema:name Springer Nature - SN SciGraph project
92 rdf:type schema:Organization
93 N5d68c2b06c41491f8aaf4f03e404024f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Skin Neoplasms
95 rdf:type schema:DefinedTerm
96 N640289673c4f4ee99871349c7a270e2f rdf:first sg:person.01352632550.56
97 rdf:rest N283d770b15e5497bad0d4ff6d4d09abf
98 N707d4805e5874f63a7263e3bc86a9da2 schema:name readcube_id
99 schema:value 4ad3643b910511b73e6ea79ffec86cb6693f0483d8ac9086bd5b2c920bb7edbc
100 rdf:type schema:PropertyValue
101 N7e4eefb06c7348959a447392f07e48af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Humans
103 rdf:type schema:DefinedTerm
104 N882f66cdcf1a4cfa8e40c4e94f6770c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name CTLA-4 Antigen
106 rdf:type schema:DefinedTerm
107 N8b307d9293054838aeecda606d5d61ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Adult
109 rdf:type schema:DefinedTerm
110 N9120216f653548218edf9b778271636a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Clinical Trials as Topic
112 rdf:type schema:DefinedTerm
113 Na629c83e42e94428b0a698a5e50cd176 rdf:first sg:person.01116772254.55
114 rdf:rest Nb23d9ab78f1346a6aa9d8ff92a615c14
115 Na76ce23143bd4623bc4443495b322965 schema:issueNumber 8
116 rdf:type schema:PublicationIssue
117 Na939490b34d342d596a21c02fdfc05e6 rdf:first sg:person.01123052323.79
118 rdf:rest N38b53e9cec304407a14645323f03e74d
119 Naf233fe2c8454130bdf5eb9d4514695c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Antigens, CD
121 rdf:type schema:DefinedTerm
122 Nb1e18d44975b42c2aba2af424bbce1f7 schema:volumeNumber 58
123 rdf:type schema:PublicationVolume
124 Nb23d9ab78f1346a6aa9d8ff92a615c14 rdf:first sg:person.01070050076.50
125 rdf:rest Nc90539e4f26a4196bff0d383a5e8c801
126 Nb83199ab97ce4a35895c0c8bdc57b409 schema:name nlm_unique_id
127 schema:value 8605732
128 rdf:type schema:PropertyValue
129 Nb92ef27a08284db6a88289de05b28729 rdf:first sg:person.0740661020.21
130 rdf:rest N563e5890cefd4b81b42dbf1bc2cb2bf0
131 Nc90539e4f26a4196bff0d383a5e8c801 rdf:first sg:person.0603211266.70
132 rdf:rest N3be1faa63fe545f3bdf19c762b4fb954
133 Nda9e33c64e0e4c47ac5d1331141ae371 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Male
135 rdf:type schema:DefinedTerm
136 Ne1b08611521842ff9b4f0a5760a980b1 schema:name doi
137 schema:value 10.1007/s00262-008-0642-y
138 rdf:type schema:PropertyValue
139 Ne2f5f71e74cb413b8cd66bc49f4b247a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Antibodies, Monoclonal
141 rdf:type schema:DefinedTerm
142 Neadbb01d137d46778b08be43ea0624e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Ipilimumab
144 rdf:type schema:DefinedTerm
145 Nedf1b74a07f84b5796589aa8db043812 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Female
147 rdf:type schema:DefinedTerm
148 Nf4ead7b65e864f3ead01b56771997611 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Aged
150 rdf:type schema:DefinedTerm
151 Nf53262e478664c1fb5d3c749972f010a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Granzymes
153 rdf:type schema:DefinedTerm
154 Nf7d9b62e4a494783affe22d94ab569c0 schema:affiliation https://www.grid.ac/institutes/grid.411477.0
155 schema:familyName Carlucci
156 schema:givenName Dora
157 rdf:type schema:Person
158 Nfa23e3b31cc445d1840e93161c17e271 rdf:first Nf7d9b62e4a494783affe22d94ab569c0
159 rdf:rest Nb92ef27a08284db6a88289de05b28729
160 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
161 schema:name Medical and Health Sciences
162 rdf:type schema:DefinedTerm
163 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
164 schema:name Oncology and Carcinogenesis
165 rdf:type schema:DefinedTerm
166 sg:journal.1096240 schema:issn 0340-7004
167 1432-0851
168 schema:name Cancer Immunology, Immunotherapy
169 rdf:type schema:Periodical
170 sg:person.01050657054.88 schema:affiliation https://www.grid.ac/institutes/grid.411477.0
171 schema:familyName Calabrò
172 schema:givenName Luana
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050657054.88
174 rdf:type schema:Person
175 sg:person.01061427172.10 schema:affiliation https://www.grid.ac/institutes/grid.418321.d
176 schema:familyName Maio
177 schema:givenName Michele
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061427172.10
179 rdf:type schema:Person
180 sg:person.01063522603.80 schema:affiliation https://www.grid.ac/institutes/grid.411477.0
181 schema:familyName Biagioli
182 schema:givenName Maurizio
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063522603.80
184 rdf:type schema:Person
185 sg:person.01070050076.50 schema:affiliation https://www.grid.ac/institutes/grid.411477.0
186 schema:familyName Danielli
187 schema:givenName Riccardo
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070050076.50
189 rdf:type schema:Person
190 sg:person.01116772254.55 schema:affiliation https://www.grid.ac/institutes/grid.411477.0
191 schema:familyName Di Giacomo
192 schema:givenName Anna Maria
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116772254.55
194 rdf:type schema:Person
195 sg:person.01123052323.79 schema:affiliation https://www.grid.ac/institutes/grid.411477.0
196 schema:familyName Altomonte
197 schema:givenName Maresa
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123052323.79
199 rdf:type schema:Person
200 sg:person.01352632550.56 schema:affiliation https://www.grid.ac/institutes/grid.411477.0
201 schema:familyName Mazzei
202 schema:givenName Maria Antonietta
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352632550.56
204 rdf:type schema:Person
205 sg:person.01360274573.21 schema:affiliation https://www.grid.ac/institutes/grid.411477.0
206 schema:familyName Volterrani
207 schema:givenName Luca
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360274573.21
209 rdf:type schema:Person
210 sg:person.0603211266.70 schema:affiliation https://www.grid.ac/institutes/grid.411477.0
211 schema:familyName Guidoboni
212 schema:givenName Massimo
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603211266.70
214 rdf:type schema:Person
215 sg:person.0740661020.21 schema:affiliation https://www.grid.ac/institutes/grid.411477.0
216 schema:familyName Miracco
217 schema:givenName Clelia
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740661020.21
219 rdf:type schema:Person
220 https://app.dimensions.ai/details/publication/pub.1077591019 schema:CreativeWork
221 https://doi.org/10.1002/14651858.cd005413.pub2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037337648
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1002/cncr.23086 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010896709
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1016/j.soc.2005.12.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023784292
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1016/s1359-6349(07)71459-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029251445
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1097/01.cji.0000208259.73167.58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003604986
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1159/000082121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011274228
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1200/jco.1999.17.7.2105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549817
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1200/jco.2005.04.5716 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003868054
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1200/jco.2005.06.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021025524
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1200/jco.2005.23.16_suppl.7525 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079369791
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1200/jco.2006.10.2822 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001819704
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1200/jco.2008.26.15_suppl.3008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079371247
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1200/jco.2008.26.15_suppl.3020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079371250
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1200/jco.2008.26.15_suppl.9063 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079374683
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1634/theoncologist.12-7-864 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016305749
250 rdf:type schema:CreativeWork
251 https://www.grid.ac/institutes/grid.411477.0 schema:alternateName Azienda Ospedaliera Universitaria Senese
252 schema:name Department of Pathology, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy
253 Department of Radiology, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy
254 Division of Dermatology, Istitutto Toscano Tumori, University Hospital of Siena, Siena, Italy
255 Division of Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy
256 rdf:type schema:Organization
257 https://www.grid.ac/institutes/grid.418321.d schema:alternateName Centro di Riferimento Oncologico
258 schema:name Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
259 Division of Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, Siena, Italy
260 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...